CD8A and plasma cell myeloma: In this regard, hematologic tumors may be more representative; Leone et al. [46, 47] found that DCs accumulate in the bone marrow of myeloma patients will protect tumor plasma cells from CD8+ T cell killing, and bone marrow endothelial cells (ECs) can sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients.